Compare Intel Corp (INTC) vs Merck & Co., Inc. (MRK) Price & Performance

Intel CorpTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Intel Corp vs Merck & Co., Inc. — how do they compare? Intel Corp trades at $105.45 (market cap $487.82B), while Merck & Co., Inc. trades at $126.29 (market cap $307.25B). The key difference: Intel Corp is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.

	INTC	MRK
Market Cap	$487.82B	$307.25B
Volume	43,552,012	—
Sector	Technology	Health
52-Week High	$140.94	$129.52
52-Week Low	$19.31	$77.60
Enterprise Value	$500.07B	$350.66B
Dividend Yield	2.24%	2.73%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intel Corp

No Aura AI signal available yet.

Merck & Co., Inc.

MRK trades at $126.33, down 0.92% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, beating EPS estimates in recent quarters. Analyst consensus is bullish with a $137.30 price target, and recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

The outlook for MRK is positive, supported by robust profitability and strategic acquisitions, though risks include rising debt levels and competitive pressures. The stock offers a dividend yield with a recent $0.85 payout, and institutional buying activity indicates confidence in long-term growth prospects.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INTC

Intel earnings expected to show high volatility amid AI-driven demand shifts and manufacturing turnaround.Alex Lavoie · 8 hours agoNeutral Analysts raise Intel price targets ahead of Q2 2026 earnings on strong AI and server demand.Finbold · 11 hours agoBullish Chip stocks and strong earnings lift U.S. futures amid ceasefire hopes easing oil prices.FXEmpire · 11 hours agoBullish View details →

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 3 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.